120.20
+1.80
+(1.52%)
At close: January 10 at 8:56:54 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 5 | 20 | 20 |
| Avg. Estimate | 1.15B | 187.67M | 2.64B | 2.54B |
| Low Estimate | 853.66M | 145M | 2.4B | 1.81B |
| High Estimate | 1.75B | 242.9M | 2.86B | 3.37B |
| Year Ago Sales | 1.48B | 187.6M | 3.82B | 2.64B |
| Sales Growth (year/est) | -22.18% | 0.04% | -30.79% | -4.04% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 22UA.F | -- | -- | -- | -- |
| S&P 500 | 8.70% | 11.55% | 14.03% | 13.42% |
Upgrades & Downgrades
| Initiated | Truist Securities: Buy | 1/10/2025 |
| Initiated | Wells Fargo: Overweight | 12/11/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/27/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 11/26/2024 |
| Upgrade | Evercore ISI Group: In-Line to Outperform | 11/19/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/18/2024 |
Related Tickers
5CV.F CureVac N.V.
4.1500
+4.27%
0QF.F Moderna, Inc.
41.08
-4.00%
5CV.DE CureVac N.V.
4.2660
+9.61%
NVV1.F Novavax, Inc.
8.89
-6.92%
MRNA.VI Moderna, Inc.
41.58
-1.36%
GBM.MU Inovio Pharmaceuticals Inc. R
2.0400
0.00%
UR9.SG Clinuvel Pharmaceuticals Ltd
6.87
+0.73%
5KW.F SkinBioTherapeutics plc
0.1720
+1.18%
7IZ.MU Ziccum AB
0.0298
-29.72%
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%